Cleviprex

Cleviprex is a brand name of clevidipine, approved by the FDA in the following formulation(s):

CLEVIPREX (clevidipine butyrate - emulsion; intravenous)

• 
  Manufacturer: MEDICINES CO
  
  Approval date: August 1, 2008
  
  Strength(s): 25MG/50ML (0.5MG/ML) ^[RLD], 50MG/100ML (0.5MG/ML) ^[RLD]

Has a generic version of Cleviprex been approved?

No. There is currently no therapeutically equivalent version of Cleviprex available.

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Cleviprex. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: About generic drugs.

Related Patents

Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.

• 
  Pharmaceutical emulsion
  Patent 5,739,152
  Issued: April 14, 1998
  Inventor(s): Andersson; Kjell Hjalmar & Byrod; Eva Kristina & Hansson; Anna-Carin & Nordlander; Margareta & Westerlund; Rolf Christer
  Assignee(s): Astra Aktiebolag
  A pharmaceutical emulsion for intravenous administration is disclosed which comprises a) a short acting dihydropyridine compound; b) a lipid phase; c) an emulsifier and d) water or a buffer.
  
  Patent expiration dates:
  
  
  • April 14, 2015
    
    ✓ 
    Patent use: CLEVIPREX IS A DIHYDROPYRIDINE CALCIUM CHANNEL BLOCKER INDICATED FOR THE REDUCTION OF BLOOD PRESSURE WHEN ORAL THERAPY IS NOT FEASIBLE OR NOT DESIRABLE
    ✓ 
    Drug product
  
  



• 
  Short-acting dihydropyridines
  Patent 5,856,346
  Issued: January 5, 1999
  Inventor(s): Andersson; Kjell Hjalmar & Nordlander; Margareta & Westerlund; Rolf Christer
  Assignee(s): Astra Aktiebolag
  Compounds of the general formula ##STR1## wherein R.sub.1 and R.sub.2 are independently selected from the group consisting of hydrogen, chloro, bromo, nitro, cyano, trifluoromethyl, and R.sub.3 and R.sub.4 are independently selected from straight or branched lower (1-5 carbon atoms) alkyl groups, and including all optical isomers, provided that when R.sub.3 is methyl and R.sub.4 is tert.-butyl, then R.sub.1 /R.sub.2 are not hydrogen/hydrogen, hydrogen/2'-trifluormethyl, 2'-chloro/3'-chloro, and when R.sub.3 is methyl and R.sub.1 /R.sub.2 is hydrogen/3'-nitro, then R.sub.4 are not methyl, ethyl, propyl, iso-propyl, tert.-butyl, processes for their preparation, pharmaceutical preparations containing them and the use of the compounds in lowering the blood pressure.
  
  Patent expiration dates:
  
  
  • January 5, 2016
    
    ✓ 
    Patent use: CLEVIPREX IS A DIHYDROPYRIDINE CALCIUM CHANNEL BLOCKER INDICATED FOR THE REDUCTION OF BLOOD PRESSURE WHEN ORAL THERAPY IS NOT FEASIBLE OR NOT DESIRABLE
    ✓ 
    Drug substance
    ✓ 
    Drug product
  
  

Related Exclusivities

Exclusivity is exclusive marketing rights granted by the FDA upon approval of a drug and can run concurrently with a patent or not. Exclusivity is a statutory provision and is granted to an NDA applicant if statutory requirements are met.

• Exclusivity expiration dates:
  • August 1, 2013 - NEW CHEMICAL ENTITY
  
  

See also...

• Cleviprex Consumer Information (Drugs.com)
• Cleviprex Consumer Information (Wolters Kluwer)
• Cleviprex Consumer Information (Cerner Multum)
• Cleviprex Advanced Consumer Information (Micromedex)
• Clevidipine Consumer Information (Wolters Kluwer)
• Clevidipine Consumer Information (Cerner Multum)
• Clevidipine Intravenous Advanced Consumer Information (Micromedex)